COMPANY
QurCan Therapeutics
Toronto-based biotech developing genetic medicines for diseases of the central and peripheral nervous systems, using its TERP polymer-lipid nanoparticle platform to deliver mRNA, DNA and oligonucleotide payloads. From company website Source · Sep 15, 2026
Timeline
- Partnership Exclusive research collaboration with Eli Lilly and Company for CNS and PNS genetic medicines, with a strategic investment from Lilly. Source: company press release. source ↗